Administration of Allogenic of Red Blood Cells Loaded L-Asparaginase in Acute Lymphoblastic Leukemia Relapse.

Trial Profile

Administration of Allogenic of Red Blood Cells Loaded L-Asparaginase in Acute Lymphoblastic Leukemia Relapse.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2012

At a glance

  • Drugs ERY-ASP (Primary) ; Asparaginase
  • Indications Acute lymphoblastic leukaemia
  • Focus Pharmacodynamics
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 10 Jan 2012 Actual end date (1 Mar 2009 ) added as reported by ClinicalTrials.gov.
    • 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Results published in the British Journal of Haematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top